title: Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
abstract: The presence of estrogen receptor (ER) in breast cancer is a prognostic indicator for both disease-free and overall survival. 16α-(18)F-fluoro-17β-estradiol ((18)F-FES) with PET is a noninvasive test for evaluation of ER expression and has been used for predicting response to endocrine therapy in patients with ER-positive metastatic breast cancer. The purpose of this study was to correlate (18)F-FES PET and ER expression in patients with primary, operable breast cancer.
  
  
  METHODS
  Forty-eight patients were prospectively enrolled in an institutional review board-approved protocol and signed an informed consent form. All patients had undergone (18)F-FES PET preoperatively. Clinical characteristics, tumor characteristics, and treatment outcomes were recorded. Immunohistochemical analysis for ER and progesterone receptor (PgR) percentage expression (46 surgical, 2 core biopsy specimens) was performed. (18)F-FES PET standardized uptake value (SUV) of the breast lesion was correlated with percentage immunohistochemistry ER and PgR expression. (18)F-FES PET SUV was quantified, with a value of 1.5 or more considered positive, and ER and PgR was quantified, with 1% or more considered positive. Formalin-fixed paraffin-embedded tissue was available for 44 patients (42 surgical, 2 core biopsy specimens). We used a microarray platform, and estrogen-related gene expression data (ESR1, ESR2, and PGR) were compared with (18)F-FES PET SUV (Spearman rank correlation). Tumor size, ductal histology, grade, HER2-neu overexpression, PgR expression, estradiol level, body mass index (BMI), and lean BMI were compared with (18)F-FES PET uptake using univariate and multivariate analysis.
  
  
  RESULTS
  Forty-eight patients completed our protocol, and 2 patients did not undergo surgery because bone metastases were identified preoperatively on (18)F-FES PET. Eighty-three percent of our patients were stage I or II, with a median tumor size of 1.9 cm. Forty-one patients underwent a sentinel node biopsy. Twenty-one patients had nodal involvement. (18)F-FES PET identified 5 patients with axillary nodal uptake (median SUV, 3.0; range, 1.7-6.9). These 5 patients had ER-positive breast cancer, and all had more than 4 positive nodes at the time of axillary node dissection. (18)F-FES PET SUV was associated with immunohistochemistry ER expression. The sensitivity and specificity of the (18)F-FES PET for the breast lesion were 0.85 and 0.75, respectively. Estrogen and progesterone gene expression (ESR1, ESR2, and PGR) was not associated with (18)F-FES PET SUV (Spearman rank correlation). We found a significant correlation between (18)F-FES PET SUV and tumor size (P = 0.0015) but not with ductal histology, grade, HER2-neu overexpression, PgR, estradiol, BMI, or lean BMI (logistic regression). ER expression (P < 0.001) and tumor size (P < 0.0001) were significant on multivariate regression analysis.
  
  
  CONCLUSIONS
  (18)F-FES PET SUV correlated with ER immunohistochemistry expression but not gene expression in our patients with early breast cancer. We found that size of primary tumor was significantly associated with (18)F-FES PET SUV. (18)F-FES PET is highly predictive for metastatic disease and helped in the identification of patients with metastatic disease in a preoperative setting.
authors: Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors: Mary L
authors: ML
authors: Gemignani
authors: Sujata
authors: S
authors: Patil
authors: Venkatraman E
authors: VE
authors: Seshan
authors: Michelle
authors: M
authors: Sampson
authors: John L
authors: JL
authors: Humm
authors: Jason S
authors: JS
authors: Lewis
authors: Edi
authors: E
authors: Brogi
authors: Steven M
authors: SM
authors: Larson
authors: Monica
authors: M
authors: Morrow
authors: Neeta
authors: N
authors: Pandit-Taskar
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D004958:Estradiol / Q000031:analogs & derivatives; D005240:Feasibility Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008024:Ligands; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D059035:Perioperative Period; D049268:Positron-Emission Tomography; D011960:Receptors, Estrogen / Q000378:metabolism*
chemical_list: D008024:Ligands; D011960:Receptors, Estrogen; D004958:Estradiol; C043436:16-fluoroestradiol
keywords: PET imaging; breast cancer; estrogen receptor; ligand
references: J Nucl Med. 1995 Oct;36(10):1766-74
references: 7562040
references: Nucl Med Biol. 2011 Oct;38(7):969-78
references: 21982568
references: Clin Cancer Res. 1996 Jun;2(6):933-9
references: 9816253
references: Int J Rad Appl Instrum A. 1986;37(3):217-21
references: 3019933
references: Radiology. 1988 Oct;169(1):45-8
references: 3262228
references: J Nucl Med. 1991 Aug;32(8):1526-31
references: 1869973
references: Lancet. 2011 Aug 27;378(9793):771-84
references: 21802721
references: J Nucl Med. 2008 Mar;49(3):367-74
references: 18287268
references: J Pharm Pharm Sci. 2007;10(2):256s-265s
references: 17718929
references: J Clin Oncol. 2006 Jun 20;24(18):2793-9
references: 16682724
references: Cancer. 2005 Jan 1;103(1):164-73
references: 15565575
references: Clin Cancer Res. 2011 Jul 15;17(14):4799-805
references: 21750198
references: J Nucl Med. 1984 Nov;25(11):1212-21
references: 6092569
references: Br J Cancer. 1989 Apr;59(4):636-8
references: 2713250
references: Eur J Cancer Clin Oncol. 1988 Dec;24(12):1899-901
references: 3220086
references: J Clin Oncol. 2001 Jun 1;19(11):2797-803
references: 11387350
references: Cancer. 1986 Mar 15;57(6):1171-80
references: 3943040